奥氮平引起的神经阻滞剂恶性综合征。
Olanzapine induced neuroleptic malignant syndrome.
机构信息
Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
出版信息
Indian J Pharmacol. 2013 Jan-Feb;45(1):98-9. doi: 10.4103/0253-7613.106448.
Abstract
An 18 year old male diagnosed as a case of bipolar affective disorder (BPAD), developed neuroleptic malignant syndrome (NMS) following treatment with olanzapine (20 mg per day), an atypical antipsychotic drug. NMS is usually seen with typical antipsychotic drugs. The patient was diagnosed as a case of NMS, offending agent was immediately withdrawn and prompt treatment with bromocriptine and levodopa produced a good recovery. The various features of the case are discussed in view of the potential mortality of the syndrome.
摘要
一位 18 岁男性被诊断为双相情感障碍（BPAD）病例，在接受奥氮平（每天 20 毫克）治疗后出现了神经阻滞剂恶性综合征（NMS），奥氮平是一种非典型抗精神病药物。通常情况下，典型的抗精神病药物会引起 NMS。该患者被诊断为 NMS 病例，立即停用致病药物，并用溴隐亭和左旋多巴进行迅速治疗后恢复良好。鉴于该综合征的潜在死亡率，对该病例的各种特征进行了讨论。
相似文献
1
Olanzapine induced neuroleptic malignant syndrome.奥氮平引起的神经阻滞剂恶性综合征。
Indian J Pharmacol. 2013 Jan-Feb;45(1):98-9. doi: 10.4103/0253-7613.106448.
2
Atypicality in presentation of neuroleptic malignant syndrome caused by olanzapine.奥氮平所致抗精神病药恶性综合征的非典型表现
Indian J Med Sci. 2007 Oct;61(10):570-3.
3
Neuroleptic malignant syndrome in an adolescent receiving olanzapine-lithium combination therapy.一名接受奥氮平-锂盐联合治疗的青少年发生了抗精神病药恶性综合征。
Pharmacotherapy. 2003 Feb;23(2):255-9. doi: 10.1592/phco.23.2.255.32091.
4
Neuroleptic malignant syndrome associated with olanzapine.与奥氮平相关的抗精神病药恶性综合征。
Ann Pharmacother. 1998 Nov;32(11):1158-9. doi: 10.1345/aph.18151.
5
Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases.小儿患者中与非典型抗精神病药物相关的神经阻滞剂恶性综合征：已发表病例综述
J Clin Psychiatry. 2008 Jul;69(7):1157-65. doi: 10.4088/jcp.v69n0716.
6
Olanzapine-induced Neuroleptic Malignant Syndrome.奥氮平所致的抗精神病药恶性综合征。
Indian J Psychol Med. 2017 May-Jun;39(3):364-365. doi: 10.4103/0253-7176.207320.
7
Neuroleptic malignant syndrome and atypical antipsychotic drugs.抗精神病药恶性综合征与非典型抗精神病药物
J Clin Psychiatry. 2004 Apr;65(4):464-70. doi: 10.4088/jcp.v65n0403.
8
Olanzapine induced neuroleptic malignant syndrome--a case review.奥氮平诱发的抗精神病药恶性综合征——病例回顾
Hum Psychopharmacol. 2003 Jun;18(4):301-9. doi: 10.1002/hup.483.
9
[Use of olanzapine in adolescent with bipolar disorder after neuroleptic malignant syndrome].
Braz J Psychiatry. 2008 Mar;30(1):86. doi: 10.1590/s1516-44462008000100015.
10
Neuroleptic malignant syndrome associated with the use of prochlorperazine in a patient with a recent history of antipsychotic-induced neuroleptic malignant syndrome.与近期抗精神病药引起的神经阻滞剂恶性综合征病史相关，使用丙氯拉嗪引起的神经阻滞剂恶性综合征。
Ann Pharmacother. 2011 Nov;45(11):e61. doi: 10.1345/aph.1Q325. Epub 2011 Oct 4.
引用本文的文献
1
Neuroleptic Malignant Syndrome in a Patient With Anti-N-Methyl-D-Aspartate Receptor Encephalitis: Case Report and Review of Related Literature.一名抗N-甲基-D-天冬氨酸受体脑炎患者的抗精神病药恶性综合征：病例报告及相关文献综述
Neurohospitalist. 2022 Jan;12(1):80-85. doi: 10.1177/19418744211002978. Epub 2021 Mar 19.
2
Neuroleptic malignant syndrome in a young adult female at the university of Benin Teaching Hospital: a case report.贝宁大学教学医院一名年轻成年女性的抗精神病药恶性综合征：病例报告
Afr Health Sci. 2018 Sep;18(3):786-789. doi: 10.4314/ahs.v18i3.37.
3
Neuroleptic malignant syndrome in a patient with stable dose of olanzapine.使用稳定剂量奥氮平的患者发生神经阻滞剂恶性综合征。
J Family Med Prim Care. 2017 Jan-Mar;6(1):158-160. doi: 10.4103/2249-4863.214969.
4
Olanzapine-Induced Neuroleptic Malignant Syndrome.奥氮平所致的抗精神病药恶性综合征
Iran J Med Sci. 2017 May;42(3):306-309.
5
Sudden discontinuation and reinstitution of olanzapine-associated atypical neuroleptic malignant syndrome in a patient undergoing lung surgery.一名接受肺部手术的患者中，奥氮平相关非典型抗精神病药恶性综合征的突然停药与重新用药情况。
Int J Clin Exp Med. 2015 Jul 15;8(7):11639-41. eCollection 2015.
6
[Pharmacotherapy of psychiatric acute and emergency situations: General principles].[精神科急性和紧急情况的药物治疗：一般原则]
Nervenarzt. 2015 Sep;86(9):1097-110. doi: 10.1007/s00115-014-4148-x.
7
Catatonia versus neuroleptic malignant syndrome: the diagnostic dilemma and treatment.紧张症与抗精神病药物恶性综合征：诊断困境与治疗
Ind Psychiatry J. 2014 Jul-Dec;23(2):163-5. doi: 10.4103/0972-6748.151703.
8
[Association of atypical neuroleptics with anticonvulsants and malignant syndrome. Report of 2 cases].[非典型抗精神病药物与抗惊厥药及恶性综合征的关联。2例报告]
Pan Afr Med J. 2014 Jul 16;18:220. doi: 10.11604/pamj.2014.18.220.4868. eCollection 2014.
9
An atypical case of neuroleptic malignant syndrome precipitated by valproate.丙戊酸盐诱发的非典型抗精神病药恶性综合征病例
BMJ Case Rep. 2014 Mar 6;2014:bcr2013202578. doi: 10.1136/bcr-2013-202578.
本文引用的文献
1
Prevalence of neuroleptic malignant syndrome in 672 consecutive male in-patients.672 例连续男性住院患者中神经阻滞剂恶性综合征的患病率。
Indian J Psychiatry. 2009 Jul-Sep;51(3):202-5. doi: 10.4103/0019-5545.55089.
2
[Neuroleptic malignant syndrome and atypical antipsychotics: a brief review].[抗精神病药恶性综合征与非典型抗精神病药物：简要综述]
Encephale. 2008 Dec;34(6):618-24. doi: 10.1016/j.encep.2007.11.007. Epub 2008 Apr 2.
3
A method for estimating the probability of adverse drug reactions.一种估算药物不良反应概率的方法。
Clin Pharmacol Ther. 1981 Aug;30(2):239-45. doi: 10.1038/clpt.1981.154.
4
Preventability and severity assessment in reporting adverse drug reactions.药品不良反应报告中的可预防性和严重程度评估
Am J Hosp Pharm. 1992 Sep;49(9):2229-32.
Zotero 插件